Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 8:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 16,102 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin Disorder Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation

NCT03254784
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Arthritic Psoriasis, Psoriasis, Inflammatory Bowel Diseases
Interventions
BMS-986165 Capsule, BMS-986165 Tablet
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Oct 25, 2026, 8:45 AM EDT
Not listed Phase 1Phase 2 Interventional

Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Women With Metastatic Breast Cancer

NCT00002628
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, carboplatin, cyclophosphamide, mesna, paclitaxel, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1994
U.S. locations
3
States / cities
Indianapolis, Indiana • St Louis, Missouri • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 10, 2014 · Synced Oct 25, 2026, 8:45 AM EDT
Completed Phase 2 Interventional Results available

Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye

NCT01393132
View directory record Official record
Conditions
Dry Eye, Sjogren's Syndrome, Graft vs. Host Disease
Interventions
Thymosin Beta 4 eye drops, Vehicle Control
Drug
Lead sponsor
Michigan Cornea Consultants, PC
Other
Eligibility
18 Years to 90 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Southfield, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 23, 2015 · Synced Oct 25, 2026, 8:45 AM EDT
Completed Not applicable Interventional Results available

Efficacy of IPL Treatment of Dry Eye and Ocular Rosacea

NCT03194698
View directory record Official record
Conditions
Ocular Rosacea, Dry Eye
Interventions
Intense Pulsed Light Treatment (IPL), Meibomian Gland Expression
Device · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 100 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 3, 2020 · Synced Oct 25, 2026, 8:45 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer

NCT03480152
View directory record Official record
Conditions
Melanoma, Colon Cancer, Gastrointestinal Cancer, Genitourinary Cancer, Hepatocellular Cancer
Interventions
National Cancer Institute (NCI)-4650, a messenger ribonucleic acid (mRNA)-based, Personalized Cancer Vaccine
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 2, 2020 · Synced Oct 25, 2026, 8:45 AM EDT
Completed No phase listed Observational

Diagnostic Procedures in Women With Locally Advanced Breast Cancer Who Are Receiving Chemotherapy Before Breast Cancer Surgery

NCT00033397
View directory record Official record
Conditions
Breast Cancer
Interventions
biopsy, magnetic resonance imaging, radiomammography, ultrasound imaging, gadopentetate dimeglumine, chemotherapy
Procedure · Radiation · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
5
States / cities
San Francisco, California • Chicago, Illinois • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2017 · Synced Oct 25, 2026, 8:45 AM EDT
Recruiting No phase listed Observational

Targeting Nociceptors in Hidradenitis Suppurativa

NCT05403710
View directory record Official record
Conditions
Hidradenitis Suppurativa, Hyperhidrosis
Interventions
Botulinum toxin
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 25, 2026, 8:45 AM EDT
Completed Phase 3 Interventional Results available

A Comparative Study Between PF-06410293 and Humira® in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis

NCT04230213
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
PF-06410293, adalimumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
4
States / cities
Bowling Green, Kentucky • Duncansville, Pennsylvania • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced Oct 25, 2026, 8:45 AM EDT
Completed Phase 3 Interventional Results available

Comparative Safety and Efficacy of Two Antiviral Treatments in the Treatment of Recurrent Herpes Simplex Labialis

NCT02265913
View directory record Official record
Conditions
Herpes Labialis
Interventions
Acyclovir 5 percent (Perrigo), Acyclovir 5 percent (Reference), Placebo cream
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
12 Years and older
Enrollment
4,076 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 22, 2021 · Synced Oct 25, 2026, 8:45 AM EDT
Completed Phase 3 Interventional

PROACT - Pre-Operative Arimidex Compared To Tamoxifen

NCT00232661
View directory record Official record
Conditions
Breast Cancer
Interventions
ARIMIDEX (anastrazole), NOLVADEX (tamoxifen)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
60 Years and older · Female only
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
13
States / cities
Santa Rosa, California • New Britain, Connecticut • Torrington, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2010 · Synced Oct 25, 2026, 8:45 AM EDT
Completed Not applicable Interventional

A Pilot Study of Acupuncture for Chemotherapy-induced Peripheral Neuropathy in Breast Cancer Patients

NCT02129686
View directory record Official record
Conditions
Taxane-induced Peripheral Neuropathy, Chemotherapy-induced Peripheral Neuropathy (CIPN), Early-Stage Breast Carcinoma, Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
Interventions
Immediate Acupuncture Group, Delayed Acupuncture Group
Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 25, 2026, 8:45 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

NCT02709889
View directory record Official record
Conditions
Malignant Melanoma, Medullary Thyroid Cancer, Glioblastoma, Large-Cell Neuroendocrine Carcinoma, Neuroendocrine Prostate Cancer, High Grade Gastroenteropancreatic Neuroendocrine Carcinoma, Other Neuroendocrine Carcinoma, Other Solid Tumors
Interventions
Rovalpituzumab tesirine, Dexamethasone
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
30
States / cities
Gilbert, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 25, 2026, 8:45 AM EDT
Completed No phase listed Observational

Quality of Life in Postmenopausal Women Who Are Receiving Either Exemestane or Anastrozole With or Without Celecoxib for Stage I, Stage II, or Stage IIIA Primary Breast Cancer

NCT00090974
View directory record Official record
Conditions
Breast Cancer
Interventions
quality-of-life assessment
Procedure
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
0 Years to 120 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
224
States / cities
Fairbanks, Alaska • Phoenix, Arizona • Fairfield, California + 144 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 25, 2026, 8:45 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis

NCT07219420
View directory record Official record
Conditions
Palmoplantar Pustulosis
Interventions
Bimekizumab, Placebo
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
8
States / cities
Birmingham, Alabama • Fremont, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 25, 2026, 8:45 AM EDT
Terminated Not applicable Interventional

Essiac (ESIAK) Versus Placebo to Improve Quality of Life in Transition in Women With Breast or Ovarian Cancer.

NCT00287482
View directory record Official record
Conditions
Ovarian Cancer, Breast Cancer
Interventions
Essiac
Drug
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 12, 2007 · Synced Oct 25, 2026, 8:45 AM EDT
Terminated No phase listed Observational

GeneSearch Breast Lymph Node (BLN) Assay Timing Study

NCT00595023
View directory record Official record
Conditions
Breast Cancer
Interventions
GeneSearch™ Breast Lymph Node (BLN) Assay
Device
Lead sponsor
Janssen Diagnostics, LLC
Industry
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
6
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Clearwater, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2016 · Synced Oct 25, 2026, 8:45 AM EDT
Completed Phase 2 Interventional

Oral Drug Study In Women With Refractory Metastatic Breast Cancer After First-line or Second-line Herceptin.

NCT00051103
View directory record Official record
Conditions
Metastatic Breast Cancer, Neoplasms, Breast
Interventions
Investigational Cancer Drug
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
30
States / cities
Chula Vista, California • Los Angeles, California • Poway, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Oct 25, 2026, 8:45 AM EDT
Completed No phase listed Observational Results available

Patient-reported Outcomes for Sarecycline Effectiveness and Safety (PROSES)

NCT04820673
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Sarecycline
Drug
Lead sponsor
Almirall, S.A.
Industry
Eligibility
9 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts • Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Oct 10, 2024 · Synced Oct 25, 2026, 8:45 AM EDT
Terminated Not applicable Interventional Results available

Oregano Ointment vs. Standard Treatment for Pediatric Atopic Dermatitis

NCT02289989
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Oregano extract cream, Hydrocortisone
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
2 Years to 17 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Somerset, New Jersey
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 25, 2026, 8:45 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Epigenetics of TNBC in Overweight and Obese Hispanic & Non-Hispanic White Women

NCT04291950
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Needle core biopsy
Procedure
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Oct 25, 2026, 8:45 AM EDT
Completed Phase 4 Interventional Results available

Milnacipran for Treatment of Pain in Older Adults With Rheumatoid Arthritis

NCT01225991
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Milnacipran
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
50 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 25, 2026, 8:45 AM EDT
Completed Phase 3 Interventional

Bioequivalence Study to Compare Sol-Gel Technologies' 5-FU Cream With Efudex® (5-FU) Cream

NCT03727074
View directory record Official record
Conditions
Actinic Keratosis (AK)
Interventions
5-FU Cream, Efudex®, Vehicle
Drug
Lead sponsor
Sol-Gel Technologies, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cerritos, California
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Oct 25, 2026, 8:45 AM EDT
Not yet recruiting Not applicable Interventional

Study of Monochromatic X-ray Mammography System

NCT07219797
View directory record Official record
Conditions
Breast Imaging, Breast Cancer
Interventions
2-D Monochromatic X-ray Mammography System
Device
Lead sponsor
Imagine Scientific, Inc.
Industry
Eligibility
40 Years and older · Female only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Oct 25, 2026, 8:45 AM EDT
Active, not recruiting Phase 1 Interventional

Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer

NCT05633979
View directory record Official record
Conditions
Breast Cancer
Interventions
Trastuzumab deruxtecan, Valemetostat
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 25, 2026, 8:45 AM EDT